	US 11,732,048 B2
	Anti-axl antagonistic antibodies
David Robert Micklem, Bergen (NO); Sergej Kiprijanov, Oslo (NO); James Bradley Lorens, Bønes (NO); Lavina Ahmed, Bergen (NO); Linn Nilsson, Bergen (NO); and Tone Sandal, Bergen (NO)
Assigned to Bergen Teknologioverføring AS, Thormøhlensgate (NO); and BerGenBio ASA, Jonas Lies vei (NO)
Filed by BERGEN TEKNOLOGIOVERFØRING AS, Bergen (NO); and BERGENBIO ASA, Bergen (NO)
Filed on Nov. 2, 2021, as Appl. No. 17/516,916.
Application 17/516,916 is a continuation of application No. 16/098,933, granted, now 11,198,734, previously published as PCT/EP2017/065313, filed on Jun. 21, 2017.
Claims priority of application No. 1610902 (GB), filed on Jun. 22, 2016.
Prior Publication US 2022/0195054 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 45/06 (2013.01); A61K 47/6801 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)]

20 Claims

1. An antibody that binds Axl and which comprises:

a. an antibody heavy chain variable region (VH) domain comprising a VH CDR1, a VH CDR2, and a VH CDR3 of SEQ ID NO: 2; and

b. an antibody light chain variable region (VL) domain selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4.